1. Investigation of mechanisms of action involved in the antidepressant-like effect of Trans,trans-farnesol in mice.
- Author
-
Delmondes GA, Pereira Lopes MJ, Borges AS, Bezerra DS, Silva JPD, Souto BS, Costa JGDS, Campos PES, Santana TI, Coutinho HDM, Barbosa-Filho JM, Alencar de Menezes IR, Bezerra Felipe CF, and Kerntopf MR
- Subjects
- Mice, Animals, Antidepressive Agents pharmacology, Antidepressive Agents therapeutic use, Depression drug therapy, Depression chemically induced, Swimming, Norepinephrine, Farnesol, Serotonin
- Abstract
This study aimed to investigate, through in vivo and biochemical methodologies, the effect of trans,trans-farnesol (12.5, 25, 50 or 100 mg/kg, p.o.) acute administration, adopting different behavioral and neurochemical parameters associated with an acute induced-depression model in mice. The initial results showed that, the oral treatment with trans,trans-farnesol, at the dose of 100 mg/kg induced a possible antidepressant-like effect in animals subjected to forced swim test (FST) and reserpine-induced akinesia. In addition, it was observed that the compound in question has an effect size and properties similar to imipramine (prototype of tricyclic antidepressants), but devoid of proconvulsant adverse effect. In biochemical assays, the pretreatment with trans,trans-farnesol, at a dose of 100 mg/kg (p.o.), decreased the hippocampal concentration of thiobarbituric acid reactive substances (TBARS) and restored striatal levels of noradrenaline and serotonin in mice subjected to FST. Altogether, these results suggest that trans,trans-farnesol showed a significant antidepressant-like effect, which seems to be mediated by the antagonism of muscarinic cholinergic receptors, reduction of oxidative stress and the modulation of noradrenaline and serotonin content in the central nervous system., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF